LO LOESTRIN FE REQUEST SAMPLES
 

Lo Loestrin® Fe is committed to providing helpful resources for your practice and your patients:

 

Request samples

To request your samples of Lo Loestrin Fe, please print out and return the Sample Request fax-back form or request online.

DOWNLOAD SAMPLE REQUEST FORM
 

Dispense as Written (DAW)

Remember to include Dispense as Written (DAW) on prescriptions, so your patients receive branded Lo Loestrin Fe at the pharmacy.

 

Lo Loestrin® Fe Savings Program

With the Lo Loestrin Fe Savings Program, eligible patients may pay as little as $25* for a 1-month or 3-month prescription fill. Consider writing a 3-month prescription for fewer trips to the pharmacy.

This offer is available to patients with commercial prescription insurance coverage and a valid prescription for Lo Loestrin® Fe. Offer not valid for use by patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs.

* Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Please click here for Program Terms, Conditions, and Eligibility Criteria.

Eligible patients can access the Lo Loestrin Fe Savings Program in the 3 following ways:

Msg and data rates apply. Msg frequency depends on user. Reply HELP for help; reply STOP to cancel. Consent to texts not required to sign up for offer.
Texting Terms: smsterms.copaysavingsprogram.com/loloestrin
Texting Privacy: smsprivacy.copaysavingsprogram.com/loloestrin

There is help for eligible patients seeking to save on their prescriptions for
Lo Loestrin Fe, even if it is non-preferred or not covered.

CALL THE SAVINGS PROGRAM NAVIGATOR SUPPORT LINE

A dedicated customer service specialist who helps answer questions from pharmacists and callback nurses about the Lo Loestrin Fe Savings Card redemption process.

The Savings Program Navigator can help answer questions related to:
  • Processing the savings card when Lo Loestrin Fe is not covered or in case of Prior Authorizations (PAs), Step-Edits, and NDC- blocks
  • Pharmacy-specific coupon processing
  • Other processing issues
     

    Getting her started

    The Lo Loestrin® Fe Patient Brochure may help patients get off to a good start with Lo Loestrin Fe. The brochure also helps patients understand their pill pack and have access to the Lo Loestrin Fe Savings Program. Use the Sample Request fax-back form to request more patient support materials.

    DOWNLOAD PATIENT BROCHURE
     
     
    INDICATION

    Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of >35 kg/m2 has not been evaluated.

    IMPORTANT SAFETY INFORMATION

    Warning: cigarette smoking and serious cardiovascular events Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.

    Contraindications

    Lo Loestrin Fe is contraindicated in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

    Warnings and Precautions

    Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

    Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternative contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. Lo Loestrin Fe should be discontinued during pregnancy.

    Adverse Reactions

    In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.

    Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

    Please see full Prescribing Information, including Boxed Warning, for Lo Loestrin Fe.

     
    REFERENCES

    1. IQVIA® National Prescription Audit® - TRx/EUTRx Data: February 2021 – January 2022  (claim derived from the use of information under license from IQVIA, which expressly reserves all rights, including rights of copying, distribution, and republication). 2. Lo Loestrin® Fe prescribing information. Madison, NJ: Allergan USA, Inc.; 2022. 3. U.S. Food and Drug Administration. The Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/. Accessed February 2022. 4. Data on file. Allergan USA, Inc.: Madison, NJ. 5. Managed Markets Insight and Technology, LLC™, a trademark of MMIT. Database as of March 2022. Data are subject to change. 6. The Alan Guttmacher Institute. Fulfilling the promise: public policy and U.S. family planning clinics. http://www.guttmacher.org/pubs/fulfill.pdf. Accessed February 2022. 7. Junel® Fe 1/20 prescribing information. North Wales, PA: Teva Pharmaceuticals USA; 2017. 8. Archer OF, Nakajima ST, Sawyer AT, et al. Obstet Gynecol. 2013;122(3):601-607. 9. Ogden CL, Carroll MD, Kit BK, Flegal KM. JAMA. 2014;311(8):806-814. 10. Nakajima ST, Archer DF, Ellman H. Contraception. 2007;75(1):16-22. 11. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Contraception. 2006;74(2):100-103. 12. Spona J, Elstein M, Feichtinger W, et al. Contraception. 1996;54(2):71-77.

    IMPORTANT SAFETY INFORMATION More Less

    Warning: cigarette smoking and serious cardiovascular events Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.

    Contraindications

    Lo Loestrin Fe is contraindicated in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

    Warnings and Precautions

    Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

    Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternative contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. Lo Loestrin Fe should be discontinued during pregnancy.

    Adverse Reactions

    In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.

    Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

    Please see full Prescribing Information, including Boxed Warning, for Lo Loestrin Fe.